394 Results for "

monkey FAP

" in MedChemExpress (MCE) Product Catalog:
Products (394)

394 Results for "monkey FAP" in MCE Product Catalog:

  • Categories Recommended:
    More
Cat. No.: HY-159098
dWIZ-1 is an orally active molecular glue and chemical probe targeting the WIZ transcription factor, which based on an IMiD backbone, binding to human WIZ with an affinity of 3.5 μM. dWIZ-1 recruits WIZ to the cereblon-DDB1 complex via its ZF7 domain, thereby triggering proteasome-dependent degradation of WIZ. dWIZ-1 significantly induces fetal hemoglobin expression in erythroblasts while reducing the level of inhibitory H3K9 dimethylation at WIZ binding sites such as the β-globin locus. Meanwhile, dWIZ-1 does not affect the proliferation and differentiation of erythroblasts, and no cytotoxicity is observed in in vitro cells or cynomolgus monkey models. dWIZ-1 serves as a critical tool molecule for investigating the mechanism and underlying pathways of sickle cell disease .
loading...
    loading...
Cat. No.: HY-159099
CAS No.: 2654011-51-3
Purity:  99.15%
WIZ degrader 9 is an orally active molecular glue degrader of the WIZ transcription factor. As a molecular glue, WIZ degrader 9 recruits WIZ to the cereblon E3 ubiquitin ligase complex via its ZF7 domain, driving proteasome-dependent degradation of WIZ. WIZ degrader 9 induces hemoglobin production, reduces the level of H3K9 dimethylation across the whole genome and at the β-globin locus, upregulates the transcription of γ-globin and BGLT3, and increases the level of histone H3K9 acetylation in the promoter region of HBG1/2. WIZ degrader 9 effectively induces fetal hemoglobin production in both mice and cynomolgus monkeys. WIZ degrader 9 can be used for research on sickle cell disease .
loading...
    loading...
Cat. No.: HY-184965
CAS No.: 2020058-38-0
Target:  

Calcium Channel

Research Areas:  

Inflammation/Immunology

S-Y048 is an orally active OXE receptor-selective antagonist with picomolar-level IC50 values (0.02-30 nM) and pIC50 values of (10.47-10.81) against human receptors. S-Y048 selectively blocks the 5-oxo-ETE signaling pathway, inhibits actin polymerization, calcium mobilization, leukocyte migration, as well as allergen-induced leukocyte infiltration in skin and lung tissues, and reduces mucin-producing bronchial epithelial cells. S-Y048 undergoes benzyl, N-methyl and α-hydroxylation reactions to form metabolites in monkeys. S-Y048 can be used in research related to asthma, allergic asthma, allergic eosinophilic diseases, atopic dermatitis and allergic rhinitis .
loading...
    loading...
Cat. No.: HY-P992524
Target:  

CD3

Research Areas:  

Cancer

PF-07260437 is a bispecific monoclonal antibody targeting B7-H4 and CD3, with Kd values of 63.5 nM and 66.75 nM against human and cynomolgus monkey CD3, respectively. PF-07260437 simultaneously binds B7-H4 on tumor cells and the CD3ε subunit in the T cell receptor complex, forming a tumor cell-bispecific antibody-T cell trimer. This process establishes an immune synapse and initiates non-MHC-dependent T cell activation, proliferation, and release of cytotoxic molecules such as granzyme B to kill tumor cells. PF-07260437 can be used in research related to advanced or metastatic breast cancer, ovarian cancer, and endometrial cancer .
loading...
    loading...
Cat. No.: HY-W017500
CAS No.: 17833-53-3
N-Methyl-DL-aspartic acid acts as an agonist for N-methyl-D-aspartic acid receptors and D-isomer-specific aspartate receptors. N-Methyl-DL-aspartic acid activates hypothalamic neurons that regulate gonadotropin-releasing hormone secretion, and stimulates prepubertal male rhesus monkeys to produce sustained intermittent gonadotropin-releasing hormone secretion and pulsatile luteinizing hormone secretion. N-Methyl-DL-aspartic acid activates excitatory effects mediated by N-methyl-D-aspartic acid receptors. N-Methyl-DL-aspartic acid exhibits convulsant effects, inducing clonic convulsions with loss of righting reflex, generalized tonic-clonic seizures or persistent clonic seizures. N-Methyl-DL-aspartic acid causes precocious puberty. N-Methyl-DL-aspartic acid can be used in studies related to convulsions and seizures .
loading...
    loading...
Cat. No.: HY-W319295
CAS No.: 3637-10-3
TEMPOL-H is the reduced hydroxylamine form of the stable nitroxide radical Tempol (HY-100561), and serves as the active metabolite of OT-551 (HY-W556870). TEMPOL-H acts as a potent antioxidant and free radical scavenger. TEMPOL-H protects retinal pigment epithelial cells from acute light-induced damage, and protects mice from lethal whole-body radiation. TEMPOL-H inhibits lens opacification in mice, prevents glutathione loss in rat lenses under stress, blocks protein leakage in rhesus monkey lenses under stress, and maintains the 3H-choline accumulation capacity of the lens. TEMPOL-H can be used in studies related to light-induced retinal pigment epithelial degeneration and age-related cataract .
loading...
    loading...
Cat. No.: HY-P991193

Target:  

TNF Receptor

Research Areas:  

Cancer

NGM-438 is a humanized monoclonal antibody antagonist of LAIR1, with a Ka of 0.26 nM for human LAIR1 and 4.28 nM for cynomolgus monkey LAIR1. NGM-438 blocks the binding of LAIR1 to its Collagen ligand and antagonizes the Collagen-induced LAIR1 signaling pathway. NGM-438 reverses FcγR signaling inhibition in myeloid cells, induces dendritic cells to secrete TNFα, promotes T cell proliferation, and triggers myeloid inflammation and allogeneic T cell responses. NGM-438 sensitizes refractory mouse lung cancer to PD-1 blockade, increases the content of intratumoral CD8 + T cells and the expression of inflammatory genes. NGM-438 is applicable to research related to solid tumors, refractory solid tumors and non-small cell lung cancer .
loading...
    loading...
Cat. No.: HY-P992024

Target:  

Interleukin Related

Research Areas:  

Inflammation/Immunology

SK48-E26 is a human interleukin-1β (IL-1β) inhibitor, with a IC50 of 400 pM against human IL-1β, a IC50 of 185 pM against cynomolgus monkey IL-1β, and a Ka value ranging from 0.048 nM to 3 nM for human IL-1β. SK48-E26 binds to the conformational epitope of human IL-1β spanning amino acid residues 95-101, and blocks the biological activity of IL-1β. SK48-E26 can be used in research related to IL-1β-mediated inflammatory diseases and osteoarthritis .
loading...
    loading...
Cat. No.: HY-N10423
CAS No.: 18423-69-3
Synonyms: (-)-Cubebin
Cubebin ((-)-Cubebin), a dibenzyl butyrolactone lignan, is an orally active AChE inhibitor. Cubebin binds to active sites of NF-κB, TNF-α, and TGF-β1 via hydrogen and hydrophobic interactions, obstructing critical residues to inhibit pro-inflammatory or renal fibrosis-related activity. Cubebin enhances p38 MAPK phosphorylation to increase tyrosinase gene expression, stimulating melanogenesis via elevated tyrosinase activity, expression, and mRNA levels. Cubebin reduces oxidative stress via enhanced endogenous antioxidant enzyme activity and inhibited lipid peroxidation, regulates lipid metabolism, improves glycemic control, and exerts renoprotective effects via reduced renal dysfunction markers and improved renal architecture. Cubebin shows antimicrobial activity. Cubebin exerts larvicidal activity against Angiostrongylus cantonensis larvae, with no cytotoxicity toward monkey or human cell lines or Caenorhabditis elegans. Cubebin can be used for the research of diabetic nephropathy, melanoma, colon adenocarcinoma, neuroangiostrongyliasis, Alzheimer’s disease (AD) and depression .
loading...
    loading...
Cat. No.: HY-116161
CAS No.: 130273-87-9
Target:  

Drug Intermediate

Research Areas:  

Cardiovascular Disease Others

15(R)-17-phenyl trinor Prostaglandin F2α isopropyl ester (15(R)-17-phenyl trinor PGF2α isopropyl ester) is the latanoprost-related isomer containing both a double bond at 13,14 and an inverted (β) hydroxyl group at C-15. Similar to 15(S)-latanoprost, 15(R)-17-phenyl trinor PGF2α isopropyl ester is a potential impurity in most commercial preparations of the latanoprost bulk drug product. The IC50 values for the free acid forms of 15(S)-17-phenyl trinor PGF2α and 15(R)-17-phenyl trinor PGF2α were determined to be 0.71 nM and 30 nM, respectively, in a FP receptor binding assay using the cat iris sphincter muscle.1 A 3 μg dose of 15(R)-17-phenyl trinor PGF2α caused a 1.9 mmHg reduction of IOP in normotensive cynomolgus monkeys.
loading...
    loading...
Cat. No.: HY-177300
CAS No.: 1402802-45-2
TLR7/8 agonist 13 is an orally active dual agonist of TLR7 (lowest effective concentrations (LEC) [hTLR7] = 1.6 μM) and TLR8 (LEC [hTLR8] = 1.6 μM). TLR7/8 agonist 13 exhibits agonistic activity against human peripheral blood mononuclear cells (hPBMCs) (LEC [hPBMC] = 0.5 μM). TLR7/8 agonist 13 induces endogenous IFNα, activating myeloid dendritic cells and monocytes toward a TH1 phenotype in mice and cynomolgus monkeys. TLR7/8 agonist 13 reduces viral load and HBV surface antigen expression in a mouse model of chronic AAV-HBV infection. TLR7/8 agonist 13 has the potential to indirectly induce IFNγ, which may promote HBV antigen-specific CD8 T cell-mediated responses. TLR7/8 agonist 13 can be used to study hepatitis B virus .
loading...
    loading...
Cat. No.: HY-P991149
CAS No.: 2966936-23-0
Synonyms: YH32367; ABL105

Target:  

TNF Receptor

Research Areas:  

Cancer

Nesfrotamig (YH32367; ABL105) is a bispecific activator targeting HER2 and 4-1BB. The Kd values of Nesfrotamig for human HER2 and human 4-1BB are 0.48 nM and 3.36 nM, respectively. By blocking tumor cell growth signals, activating HER2-dependent local 4-1BB in tumors to maintain T cell survival, and inducing NK cell-mediated antibody-dependent cellular cytotoxicity, Nesfrotamig enhances the cytotoxicity and tumor infiltration ability of immune cells. Nesfrotamig promotes the generation of tumor-specific memory T cells, drives T cell-mediated tumor lysis, exhibits significant anti-tumor efficacy against both HER2-positive and HER2-low-expressing tumors, and shows synergistic activity when combined with anti-PD-1 antibodies. In cynomolgus monkey studies, Nesfrotamig demonstrates good safety and is suitable for research related to HER2-positive and HER2-low-expressing tumors .
loading...
    loading...
Cat. No.: HY-P990688
CAS No.: 2559056-68-5
Synonyms: AMG-509

Target:  

CD3

Research Areas:  

Cancer

Xaluritamig (AMG-509) is a bispecific T cell engager and cytolytic agent with a Kd of 27.6 nM for human CD3ε. Xaluritamig binds to CD3ε via an anti-CD3 single-chain variable fragment (scFv) domain, and to STEAP1 via a bispecific anti-STEAP1 antigen-binding fragment (Fab) domain, thereby recruiting and activating T cells and forming a bridge between T cells and STEAP1-expressing cancer cells. Xaluritamig induces T cell-mediated redirected cytotoxicity, tumor cell lysis, cytokine release, CD8 + T cell activation and expansion, as well as tumor stasis or regression. Xaluritamig contains an Fc domain with no effector function, which prolongs serum half-life, exhibits only minimal activity against cells with low STEAP1 expression and normal cells, and shows extremely low target-related off-tumor toxicity in cynomolgus monkeys. Xaluritamig is used in STEAP1×CD3 XmAb 2+1 immunotherapy and in research on metastatic castration-resistant prostate cancer and Ewing sarcoma .
loading...
    loading...
Cat. No.: HY-164729
FZ-AD005 is a DLL3-targeting antibody-drug conjugate (ADC) with high selectivity, composed of the anti-DLL3 antibody FZ-A038 (HY-P990896), a dipeptide linker (Val-Ala), and DXd (HY-13631D). The Kd value of FZ-AD005 for human DLL3 ranges from 13.29 to 58.3 pmol/L. After binding to DLL3 on the cell surface, FZ-AD005 mediates endocytosis, and the payload DXd is released via cleavage by lysosomal cathepsins. DXd inhibits topoisomerase TopI to induce double-strand DNA breaks, cell cycle arrest and apoptosis, and FZ-AD005 exhibits bystander killing activity against adjacent DLL3-negative cells. FZ-AD005 shows stable circulation in vivo, has good tolerance and acceptable pharmacokinetic profiles in rats and cynomolgus monkeys, and effectively inhibits the growth of DLL3-expressing tumor cells. FZ-AD005 serves as a promising candidate molecule for research on small cell lung cancer and human neuroendocrine prostate cancer .
loading...
    loading...